Rare diseases
Investigational molecules
Locations
Gabriel-Von-Seidl-Strasse 81, Herrnsheim, 67550 Worms, Germany
Klinikum Worms gGmbH in Worms, Germany specialises in clinical trials of conditions such as Breast cancer, Breast cancer metastatic, Hormone receptor positive HER2 negative breast cancer, Atrial fibrillation, and other specialisations. This site conducts important research.
The cardiovascular research at Klinikum Worms gGmbH addresses patients with acute coronary syndrome and atrial fibrillation, aiming to test new oral anticoagulants for reducing heart attacks, strokes, and related complications.
The site’s team of seven investigators collaborates closely to generate robust data that could shape future treatment guidelines.
In the neoplasms portfolio, Klinikum Worms gGmbH focuses on ER+/HER2- early breast cancer and HER2/neu positive breast cancer, exploring innovative therapies to lower recurrence after surgery and standard adjuvant treatment.
These studies are conducted by a multidisciplinary team aiming to provide new options for women battling breast cancer.
Clinical trials currently enrolling participants at this site.
Study of BNT327 and a drug combination for patients with untreated metastatic or locally recurrent triple-negative breast cancer
GermanyStudy of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease
GermanyStudy on the Safety and Effectiveness of Trastuzumab Deruxtecan vs. Palbociclib-Based Drug Combination for Advanced HR-Positive, HER2-Low Breast Cancer Patients
GermanyStudy on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy
GermanyStudy of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer
GermanyA study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer
GermanyPhase 1b-2 Study of Elacestrant and Abemaciclib in Patients with Brain Metastases from ER-Positive, HER2-Negative Breast Cancer
GermanyA study testing zanidatamab combined with chemotherapy before surgery in patients with HER2-positive breast cancer
GermanyStudy of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk
GermanyEvaluating the Effect of Vicadrostat and Empagliflozin Combination Compared to Empagliflozin Alone in Patients with Heart Failure and Reduced Left Ventricular Function
GermanyComparison of niraparib alone versus niraparib with bevacizumab in patients with newly diagnosed advanced ovarian cancer after chemotherapy with carboplatin and paclitaxel
GermanyStudy on Elacestrant and Everolimus for Patients with Advanced ER+/HER2- Breast Cancer Resistant to Endocrine Therapy and CDK4/6 Inhibitors
GermanyGet verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
